Tocilizumab-Induced Sweet Syndrome in a Patient With Polymyalgia Rheumatica

Tocilizumab-Induced Sweet Syndrome in a Patient With Polymyalgia Rheumatica

Authors

  • Federica Filippi Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna
  • Marco A. Chessa Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy
  • Annalisa Patrizi Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna
  • Carlotta Baraldi Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna
  • Francesca Ferrara Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna
  • Federico Bardazzi Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna

Keywords:

tocilizumab, tocilizumab-induced Sweet syndrome, drug-induced Sweet syndrome, neutrophilic dermatosis

References

1. Baroni A, Piccolo V, Russo T, Cozzolino D, Mascolo M, Chessa MA. Norfloxacin-induced subacute cutaneous lupus with erythema multiforme-like lesions: the enigma of the Rowell syndrome. J DtschDermatolGes 2014;12:1039-42.

2. Walker D C, Cohen P R. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996;34:918-23.

Downloads

Published

2019-12-31

Issue

2020 Vol 10, No 1 | January

Section

Letter

License

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

1.
Tocilizumab-Induced Sweet Syndrome in a Patient With Polymyalgia Rheumatica . Dermatol Pract Concept [Internet]. 2019 Dec. 31 [cited 2024 Apr. 16];:e2020019. Available from: https://www.dpcj.org/index.php/dpc/article/view/dermatol-pract-concept-articleid-dp1001a19

Share